• Company
• Luxturna, a one-shot retinal disease treatment
• by Eo, Yun-Ho Apr 11, 2023 06:11am

• InterView
• CDK4/6 latecomer Kisqali exudes confidence in its effect
• by Jung, Sae-Im Apr 11, 2023 06:11am

• Company
• One-shot CAR-T tx, approved for domestic items
• by Eo, Yun-Ho Apr 11, 2023 06:11am

• Company
• Roche and Korea BIO offers opportunity to domestic companies
• by Hwang, Jin-joon Apr 11, 2023 06:08am

• Policy
• 3 combination DM drug is cheaper than the 2 combi
• by Lee, Tak-Sun Apr 10, 2023 05:53am

• Policy
• Reimb review for Pompe disease drug Nexviazyme underway
• by Lee, Tak-Sun Apr 10, 2023 05:53am

• Company
• Two types of RET-targeted anti-cancer drugs for minority pts
• by Eo, Yun-Ho Apr 10, 2023 05:52am

• Policy
• Only a few cold drugs will be subject to PVA negotiations
• by Lee, Tak-Sun Apr 10, 2023 05:52am

• Company
• It is difficult to secure domestic funding for bio ventures
• by Hwang, Jin-joon Apr 10, 2023 05:51am

• Company
• GemVax’s Alzheimer’s Tx GV1001 receives IND approval
• by Kim, Jung-Ju Apr 7, 2023 05:55am